RxDoctor Payments Data

Kristin Rabaut

Optometrist · Louisville, KYNPI 1326239930

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,903 of the $4,809 with a category attached, or 81.2%. 17 manufacturers reported payments, led by Alcon at 43.5% of the total. Reporting peaked in 2019 at $1,982 and has fallen 82.3% since, to $350 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,809in general payments, 2019–2025

Across 123 payments — averaging $39.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Vision Care, Inc.$582
  • AbbVie$437
  • Oyster Point Pharma, Inc.$266
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$221
  • Kala Pharmaceuticals, Inc.$174
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$90619%
  • Food & beverage$3,90381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,809 in reported general payments places this provider in the 90th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$41,160
Medicare patients
302
Services billed
4,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$28,731
XiidraLifitegrast18$20,562
LumiganBimatoprost32$10,292
CombiganBrimonidine Tartrate/Timolol14$3,910
Travoprost14$1,044
Latanoprost139$845
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$375
Prednisolone Acetate12$329
Timolol Maleate24$178
Doxycycline Hyclate15$173
Dorzolamide Hcl11$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$437$42,93270 claims
Bausch & Lomb Americas Inc.Xiidra$173$20,56218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →